Issuu on Google+

Me d i aPl a n n e r I nt e r nat i onal Phar mac e ut i c al I ndus t r y( I PI ) i sy ourPe e r Re v i e we d, Cont e mpor ar y&Aut hor i t at i v eg ui de , f oc us i ng ont hebe s tpr ac t i c ei nOut s our c i ngManag e me ntf ort hePhar mac e ut i c al &Bi oPhar mac e ut i c al Compani e s .

“I PIi sani nv al uabl epubl i c at i on,pr ov i di ngnews aboutt hel at es tr es ear c handef f ec t i v ei ns i ght si nt o t hephar maandbi ophar m mar ket s . Wi t hi t ’ si nf or mat i onedi t or i alc ont entI PIi sagr eat r es our c ef orkeepi ngupt odat ewi t ht hel at es t r es ear c handr egul at or ygui del i nes . ” Suz anneT r oop Di r ec t or ,Medi a Buy er

www. i pi medi awor l d. com


“ Thephar maceut i cali ndust r yi scommi t t edt ot her esear ch,devel opment ,qual i t ymanuf act ur i ngandl ogi st i csofi nnovat i ve t her apeut i cmedi ci nest hatsavel i ves,r educeover al lheal t hcar ecost sandi mpr ovet hequal i t yofl i f eofpeopl ear oundt he wor l d.Thei ndust r yst r i vest ocr eat eagl obalenvi r onmentt hatf ost er si nnovat i oni npr event i ngandcur i ngdi seases,dr ug r egul at i ont hatexpedi t esappr oval sofnew chemi calandbi ol ogi calt r eat ment sf orpat i ent sandassur est heavai l abi l i t yof genui nequal i t ymedi ci nes,pat i entaccesst oi nnovat i vet her api esandpr ot ect i onf r om subst andar dandcount er f ei tpr oduct s, ket basedcompet i t i oni nt heheal t hcar esect or ,andt hedi ssemi nat i onofdr ugi nf or mat i onandet hi calpr omot i onof mar dr ugst omedi calpr of essi onal sand,wher el egal ,t opat i ent s. ” I FPMA

“Suppor t i ngTheI ndust r yThr oughCommuni cat i on” I nor dert oachi evet hi sobj ect i ve,i ti sessent i alf ort heexecut i vesoft hi sdynami ci ndust r yt oconst ant l ykeept hemsel ves educat edi nt hel at estt echnol ogy ,mar keti nf or mat i on,r egul at or yandval i dat or ygui del i nest ogai nacompet i t i veedge. I PIpr ovi desapeerr evi ewedpl at f or m addr essi ngt heent i r eout sour ci ngi ndust r yandmanagement ,t husmeet i ngt hi s demand.Edi t edbyourcar ef ul l ysel ect ededi t or i aladvi sor ypanel ,andext ensi ver esear chnet wor k,I PIpr ovi desapr oven suppor t i vemeansofcommuni cat i ont ot hephar maceut i cal ,bi ophar maceut i cal ,nut r aceut i calandmedi caldevi ces i ndust r i es.Det ai l i ngt hel at esti nr esear chandt echnol ogyi nnovat i ons,r egul at or ygui del i nes,mar ket i ngandcommuni cat i on st r at egi eswhi chwi l lenabl eal lst akehol der st obecomemor eef f i ci ent ,br i ngpr oduct st omar ketf ast er ,r educecostand makeheal t hcar eaccessi bl et oal l .

WhyAdver t i sewi t hI PI ? I PIi st heonl ypeerr evi ewedj our nalwhi ch,l ooks i nt ot heef f ect i vemanagementoft heent i r e phar maceut i cal& bi ophar maceut i calOut sour ci ng i ndust r y . Det ai l i ngt hel at esti nResear ch& Technol ogy i nnovat i ons,Dr ugDi scover yPl at f or ms, Cont r actManuf act ur i ng& Packagi ngser vi ces, Regul at or yGui del i nes,Mar ket i ng& Communi cat i onst r at egi es.I PIhel pst odays Li f eSci encesexecut i vet ost ayabr eastoft he l at esti nf or mat i on,hel pi ngt hem t omakeef f i ci ent andcostef f ect i vedeci si ons.

87%

ofoursubscr i ber sr eador l ookt hr oughI PIwi t hi n oneweekof r ecei vi ng t hei rcopy

83. 6%

ofoursubscr i ber swoul dbe ext r emel yorver yl i kel yt o r ef erI PIt oacol l eagueor cowor ker .

Reader ’ sPer s pec t i v e 83%o f s u b s c r i b e r sh a v er e n e we d s u b s c r i p t i o ny e a r o ny e a r 81% o f s u b s c r i b e r sh a v er e a dt h el a s t 4i s s u e s 62% o f s u b s c r i b e r sh a v ek e p t c o p i e so f I PI f o r f u t u r er e f e r e n c e s 11% o f s u b s c r i b e r sc o r r o s p o n dwi t ha u t h o r s 3. 2%n e ws u b s c i p t i o ne v e r yy e a r

Aut hor ’ sPer s pec t i v e 7 6%o f a u t h o r sh a v es u b mi t t e df u r t h e r a r t i c l e si nI PI 61% Ha v er e q u e s t e dr e p r i n t s

o nI PI we b s i t e

Ci r cul at i onPr of i l e

Adv er t i s er ’ sPer s pec t i v e

44% Ha dt h e i r a r t i c l ed o wn l o a d e di nPDF 8 9%o f a d v e r t i s e r sh a v er e p e a t e d 29% Ha dt h e i r a r t i c l es e a r c h e db yn a me a d v e r t i s me n t si nI PI 16% I mp a c t f a c t o r

I nt er nat i onalPhar maceut i calI ndust r yi sagl obal l y di st r i but edpubl i cat i onwi t hanest abl i shed pr esenceacr osst heWor l d. Eachquar t er l yi ssuehasahar dcopydi st r i but i on f i gur eof20, 000copi es,pr ovi di ngst r ongaccess t ot heI nt er nat i onalMar ket . I nt er nat i onalPhar maceut i calI ndust r yJ our nal i ssentdi r ect l yt okeydeci si onmaker si nt he l i f esci encei ndust r yaddr essi ngal lst akehol der s

Subsect i oni nt heI ndust r y

43. 2% Phar maceut i cal /Bi oPhar maceut i cal Compani es 7. 0% Fi neChemi calCompani es 11. 2% Cont r actManuf act ur i ngCompani es 8. 0% Anal yt i cal /Bi ochemi calLabor at or i es 6. 5% Cont r actPacker s 1% CRO 7. 6. 0% Heal t hSer vi ces 4. 0% Ot her s-i ncl udi ngspeci al i t yphar ma, dr ug( di scover y,devel opment& del i ver y)consul t ant s, f i nanci al i nst i t ut i on& gover nmentBodi es

85% Ha v eu t i l i s e dI PI o n l i n es e r v i c e s 81% Ha v ea d v e r t i s e de v e r yc o n s e c u t i v ey e a r 62% o f a d v e r t i s e r sc h o s eJ CSa b o v eo t h e r i n d u s t r yp u b l i c a t i o n s 8%

Ha v er e q u e s t e db e s p o k ed i s t r u b u t i o n

Eur ope: 8, 435 USA& Canada:6, 442 ROW: 5, 126

Di st r ubut i onbyJ obFunct i on

8% CEO/CFO/CMO 7% Medi calDi r ect or s 9% HeadsofOper at i ons 9% HeadsofPackagi ngManagement 8% HeadsofPr ocur ement 7% Cl i ni ci ans 9% HeadsofResear ch& Devel opment 7% HeadsofPr oduct i on 8% HeadsofFor mul at i onDevel opment 7% HeadsofCl i ni calTr i al s 5% Logi st i csandSuppl yChai nManager s 4% HeadsofBusi nessDevel opment /Sal esand Mar ket i ng 4% Br and/Pr oduct i onManager 4% HeadsofRegul at or yAf f ai r s


Edi t or i alTopi csandFocalAr eas

I nt er nat i onalPhar maceut i cali ndust r yi sdi vi dedi nt osi xsect i ons, i ncor por at i ngt heent i r eval ur echai noft hephar maceut i cal out sour ci ngi ndust r y . Regul at or y& Mar ketPl ace

Dr ugDi scover y, Devel opment& Del i ver y Cl i ni calResear ch

Labs,Logi st i cs, Col dChai n Suppl y

Thi ssect i oni ncor por at esi nf or mat i ononl egal , consul t i ng,r egul at or yi ni t i at i vesandpr omot i onal oppor t uni t i esf orcent r al i sedl i f esci ence or gani sat i on.wewi l lbr i ngyoui nf or mat i onon var i ousl i f esci encescl ust er ,r egi onalandcount r y speci f i ci nf or mat i onaboutLi f e-Sci ences i nnovat i onandmar ketoper at i ons. Thi ssect i onf ocusesondr ugpl at f or ms,pr ot ei n i dent i f i cat i on,chemi calent i t i esandal i ke.Fr om di scover yt odevel opment ,wewor kwi t hal lt hose i nt hi si mpor t ant‘ f i r st ’st ep,i ncl udi ngr esear ch andt echnol ogi esonhow adr ugi sbestdel i ver ed. Thi ssect i onof f er si nf or mat i ononser vi cesi nbot h cont r actandcl i ni calr esear ch.Thi ssect i on l ooksi nt oal laspect sofact i vi t i esf r om PK/PD st udi est oLat ePhaseTr i al s.I tl ooki nt ochoosi ng t her i ghtCRO, Tr i alDesi gn,Pat i entRecr ui t ement& Ret ent i on, Si t eManagement ,Dat aCapt ur e, Anal ysi sandSubmi ssi on. TheLabsSect i onLooksi nt oanal yt i cal t echnol ogi es,Labor at or yEqui pment ,I nf or mat i on Managementsyst ems.Thel ogi st i cssect i on i ncor por at esSuppl yChai nManagement ,Cl i ni cal Tr i al sSuppl yandTemper at ur eCont r ol l ed Logi st i cs

Manuf act ur i ng

Today ,t heout sour ci ngi ndust r yi sal lt hebuz z . Thi ssect i onl ooksatcust om andcont r act manuf act ur i ngst ar t i ngf r om f i nechemi cal s, act i vei ngr edi ent si nt odosagef or msand del i ver ydevi cepr oduct i ons

Packagi ng

Pr epar i ngt hepr oductf ort heenduseri sso i mpor t antt ot oday’ sconsumer .Packagi ng pl aysavi t alr ol ei nbr andi dent i t yandpat i ent engagement .Ant i -Count er f ei t i ng,pr oduct t r acki ng,br andpr ot ect i onBr ai l l e,andt amper r ei si st antt echnol ogi esar eal ldi scussedher e.

Compani esAccessed Wewor kwi t ht hebesti nt hei ndust r yt opr ovi deourr eader s wi t hval uabl e,upt odat ei nf omat i onont heLi f eSci enceSect or Compani es

Compani es

Compani es

Abbot Akz oNobel Amgen Ast el l as Ast r aZeneca BayerScher i ngAG Bi ogen Boehhr i nger -I ngel hei m BMS Cent ocor Dai chiSankyo Dabur Dr .Reddys

EI SAI Li l l y& Co Genet ech Genz yme GSK I mcl one J ohnson& J ohnson MexNeeman Medi mune Mer ckKGA Mi l l eni um Novar t i s NovaNor di sk

OneWor l dHeal t h Pf i z er Rapi dHeal t h Reci phar m Regi st r at -Mapi SanbePhar ma Sanof i -Avent i s Scher i ngPl ough Sof r i gam Swi ssPhar ma Qual ogy Wor l dCour i er Zi nsserAnal yt i c

Subj ect s Cover ed i n JCS *Pr i mar yManuf act ur i ng:API , Fi neChemi cal s ,For mul at i ons , Ex ci pi ent s * Dr ugDi s cov er y ,Del i v er y& Ther apeut i cs * Bi ophar maceut i calCont r act Manuf act ur i ng-Cel lCul t ur e, Fer ment at oi n,bi ol ogi calAPI , Genomi csandPr ot eomi cs * Out s our ci ngandCont r act Manuf act ur i ng_v al i dat i onGCP,GLPcompl oance,qual i t y cont r olandqual i t yas s ur ance *I nv es t i gat i onMedi ci nal Pr oduct s ,Cl i ni calT r i al Mat er i al sManagement s * Cl i ni calRes ear ch-Pat i ent Recr ui t ement& Ret ent i on I VRS,EDC,ePRO * Ther apeut i cSt udi es * Cont r actRes ear ch,Dr ug Di s cov er y& Dev el opment *Dr ugDel i v er y T echnol ogy & Dos agef or m Ther apeut i cAr easCover ed Pr oduct i on * Cl eanRoom *Oncol ogy T echnol ogy * CNS * Si xSi gma * Car di ovascul ar Compl i ance,PAT , *I nf ect i ousDi seases ERP *I nnov at i ons , * Der mat ol ogy Machi ner i es , * Li verDi seases T echnol ogy * Ki dneyDi seases * Mai nt enence, * Opht hal mol ogy Li f eCy cl e *I mmunol ogy/Haemat ol ogy Management * Respi r at or y * Pr i mar y& * Or t hopaedi c Secondar y * Pai n Packi ngand * Ger i at r i c Packagi ng * Gast r oent er ol ogy * Logi s t i cs& Suppl y * Pat hol ogy Chai n,T emper at ur e * Pedi at r i c Cont r ol l edLogi s t i cs . * Women’ sHeal t h St or age& * HI V/AI DS War ehous e * Vacci ne* Ant i count er f ei t i ng, Pr event abl e andBr andPr ot ect i on Di seases ( RFI D,Pi gment at i on, * Mal ar i a cov er tandov er t * Mal nut r i t i on& T echnol ogy ) UnderNut r i t i on * Pat i entI nf or mat i on, * Tr opi cal andDTCmar ket i ng * Di seases *Phy s i ci an& Heal t h wor ker * Repr oduct i ve communi cat i on


Rat eCar d& Pr omot i onalSer vi ces I nt er nat i onalPhar mac eut i c alI ndus t r ypr ov i despr i ntadv er t i s i ment sandapac kageofonl i ne s er v i c es ,dedi c at edt oas s i s ty ouwi t hy ourmar ket i ngc ampai gn. Har dCopy& EJ our nal Doubl ePage

PageLayoutDesi gn

Adver t i si ngRat es £5, 950

Pur chasi ngPower 90. 7% ofI PIr eader sar ei nvol vedi nt he deci si onofpur chasi ngpr oduct sand ser vi cesf ort hi ercompany . 21. 3%

Ful lPage

KeyDec i s i on Maker s

£2850

58. 1%

Rec ommended andi nf l uenc es , pur c has i ng

11. 3%

Makedec i s i onsas gr oups

9. 3%

Reader snoti nv ol v ed i npur c has i ngdec i s i ons

Hal fPageHor i z ont al £1, 650

Hal fPageVer t i cal £1650

Mechani calSpeci f i cat i on Repr ogr aphi cMechani calDet ai l s ( I nMi l l i met r es , Hei ghtxWi dt h, wi t h

Speci alPosi t i on

Fr ontCoverLogo: £1, 500 I nsi deFr ontCover : £5, 950 I nsi deBackCover : ` £4, 850 Out si deBackCover : £7, 250 Nextt oEdi t or ’ sLet t er :£3, 750 Nextt oCont ent sPage:£3, 750

Onl i neSer vi ces

DPS: 273x 396 ( T y pe ) 297x 420 ( T r i m) 303x 426( Bl e e d) FULLPAGE: 273x 186 ( T y pe ) 297x 210 ( T r i m) 303x 213( Bl e e d) ½ PAGEHORI ZONT AL:

CompanyPr of i l el i st i ng: 700800wor dsofyourser vi ces+Company Logo,di r ect edt oyourwebsi t e

Logo& News £600f or3Mont hs

Emai lBl ast Newsf r om yourcompanyonournewsl et t er , t hatgoest o9, 000opt edi nsubsci ber s.

Banner £500f or3mont hs

ENewsl et t er I PIE-Newsl et t ercompr i sesofl at estnews f r om t hegl obalcl i ni calr esear chi ndust r y . I tal socont ai nsl i nkst ovar i ousar t i cl es whi chwehavepubl i shedi nt hej our nal . Thi si sani dealwayf orexecut i vesi nt he i ndust r yt okeepabr eastoft hel at est m vi happeni ngsi nt hi sf astmo ngcl i ni cal r esear chenvi r onment .TheENewsl et t ergoes outi naHTMLf or matst r ai ghti nt o subscr i ber si nbox.

T y pe, T r i m, Bl eed)

Vi deo Host edonourwesbi t ef or£700,f or3mont hs

135x 186 ( T y pe ) 148x 210 ( T r i m) 151x 213( Bl e e d) ½ PAGEVERT I CLE: 273x 92 ( T y pe )297x 105 ( T r i m) 303x 108( Bl e e d) ¼ PAGE: 135x 90 ( T y pe ) El e c t r o ni cpi c t ur e so rg r aphi c sc anbes uppl i e di nt he f o l l o wi ngf o r mat s : 1. Ado bePho t o s ho pT I F F( *. t i f f ) , J PEG, PDFo rEPS 2. Ado beI l l us t r at o rEPS El e c t r o ni ci mag e s / g r aphi c smus tbes uppl i e dathi g h r e s o l ut i o n( atl e as t300dpi ) El e c t r o ni ci mag e s / g r aphi c ss ho ul dbei nCMYKc o l o ur . Pl e as edono ts e ndf i l e se mbe dde di nMi c r o s o f tWo r d Do c ume nt s . Pl e as es uppl yt he m ass e par at e at t ac hme nt s . Cl i e ntde s i g ne dadv e r t ss ho ul dbes uppl i e di no neo f t hef o l l o wi ngway s : 1. Ado beI l l us t r at o rCS2, I mag e sandGr aphi c smus t bee mbe dde d. F o nt ss ho ul dbes uppl i e di ft he yar e no te mbe dde d/ c o nv e r t e dt oo ut l i ne . 2. Ado beAc r o batPDF . Adv e r tPDFmus tbes uppl i e d o pt i mi s e df o rhi g hqual i t ypr i nt i ng . Al l c o l o ur s ( i nc . pi c t ur e s )mus tbeCMYK, noRGBo rPant o ne . T he ymus ti nc l udehi g hr e s o l ut i o ng r aphi c s( 300dpi ) ande mbe dde df o nt s . Bl e e dadv e r t smus ti nc l ude r e g i s t r at i o nmar ki ng sandbl e e d. Wear eunabl et o makeame ndme nt st oPDFf i l e s .

Phar maPubl i cat i ons,Tel :+44( 0) 2072372036,Fax:+44( 0) 2085792036,Emai l :i nf o@phar mapubs. com, TowerBr i dgeBusi nessCompl ex, Bui l di ngJ ,Uni t -413, 100cl ementr oad,London,SE164DG


Volume 5 Issue 1 – February 2013 Submission deadline – 15th January 2013 Regulatory & Marketplace > Intellectual Property & Patent Law . > Clinic to Commercialization > Child resistant packaging policies > eCTD Regulations

> Pharmacovigilance / Legislation > Quality Assurance / Quality Control > Audience Segmentation: Personalized Marketing > Market Access Strategies

Drug Discovery / Delivery & Therapeutics > Improving Antibody Efficacy > Stem Cells in Therapeutics > Fragment Based Drug Design > Injectable Pens & Self Injection > Smart Pill technology

> Oral Drug Delivery > Formulation & Excipients > Pulmonary Drug Delivery > Biologics & Therapeutics

Clinical & Medical Research > Ethics Committee & Review Boards > Biomarkers > Data Management

> Adaptive Clinical Trials – Personalised Medicine > Clinical Patient Recruitment > Late Stage Research (Phase II – IV)

Clinical Trials > Patient Recruitment & Retention > CTS / CTMS > Biodynamic > Therapeutic Vaccine

> Adaptive Clinical Trials > Pharmacokinetics (PK Studies) > Named Patient Programme

Labs & Logistics > Imaging, ECG & Core Labs > Temperature Controlled Logistics > LIMS > Margins & Operating Efficiencies

> CAP Accreditation > Analytical Labs & Testing > Cool / Cold Chain

Manufacturing > Dosage Form Production  Solids  Capsules > Aseptic Processing > Clean Room & Contamination Control > Pre-formulation

> Lean Manufacturing / Six Sigma > PAT > Tooling > Pure Water / WFI > Peptide Synthesis

Packaging > Patient Adherence Packaging > Child resistant & Senior Friendly > IV Bags & Delivery Systems

> Braille Packaging > Sterile Packaging / Sterile Closures > Moisture Barrier

Exhibitions & Conferences Attended by IPI with this issue:

> DIA Euro Meeting > BIO Trinity 2013 nd > 22 Partnership in Clinical Trials (USA) > Knowledge for Growth (ICC Ghent)

> Interphex Chicago > BIO USA > Pharmintech (Italy) > BIO Europe Spring

IPI is Peer Reviewed. Please refer to the Editorial Guidelines section on the www.ipimediaworld.com website for Peer Review Protocol and Authors Guidelines.


Volume 5 Issue 2 – May 2013 Submission deadline – 15th April 2013 Regulatory & Marketplace > Quality Assurance / Quality Control > FDA Bio Research Monitoring > Programme – Protecting Human Subjects > Intellectual Property

> lDTC Marketing > FDA/EMA / WHO – Validation & Accreditation > Insurance & Liabilities

Drug Discovery / Delivery & Therapeutics > Antibody Drugs for Oncology > Parenteral > Custom Antibodies > In vivo / In vitro > Prefilled Injection Systems

> Molecular Technology > Nano Technology > Drug Implants > Women’s Health > Tableting (New Tablet Press generation)

Clinical & Medical Research > Preclinical > Imaging Technology > IVRS / IWRS / IXRS > Phase 1 / Early Stage

> PK / PD Studies > EDC / ePRO > Physician Liability & Ethics Review > Cancer / Immunotherapy (Development of Monoclonal Antibodies)

Clinical Trials > Managing Adverse Reactions > Patient Safety & Clinical Monitoring > Comparator Drug Supply

> eClinical Solutions > CDISC > ABPI New Guidelines on Phase 1 Clinical Trials

Labs & Logistics > Imaging & Data Collection > IVRS / IWRS / IXRS > Hazardous Cargo

> Cool Chain & Cold Chain > E – Procurement > Temperature Controlled Supply Chain

Manufacturing > Pre Filled Syringes / Self Injections > Ingredients & Intermediates > Blow Fill Seal Technology > Containment Technology > Softgel Technology

> Raw Materials > Sterile Fill Finish > Lyophilisation & Freeze Drying > TOC / HPLC > The Suitability of Formulations for specific Pharmaceutical Applications

Packaging > Stability Testing & Shelf Life Management > Anti-Counterfeiting & Brand Protection > Clinical Trials Packaging

> Moisture Absorption & Moisture Barrier > RFID Coding & Marking > Patient Information

Exhibitions & Conferences Attended by IPI with this issue: th

> 49 DIA Annual Meeting > Cool Chain IQPC (USA) > World Stem Cell & Regenerative Medicine 2013 > BIO (BOSTON)

> Process & Packaging Machine > CDISC International Interchange

> EPIC

The topics and subjects listed above are special features and focuses. Please refer to the media information for a list of general topics that will be featured in IPI throughout 2013. Editorial topics listed above are subject to changes, according to the movement of the industry. We will be pleased to hear from you if you have relevant topics you would like to contribute within the journal. Please email all your suggestions to – info@pharmapubs.com Current News and Press Releases can also emailed to the above email address and will be hosted at – www.ipimediaworld.com, or featured in the IPI Weekly Newsletter at our discretion.


Volume 5 Issue 3 – August 2013 Submission deadline – 15th July 2013 Regulatory & Marketplace > ICH Regulations on Monitoring > Period on New Drugs > ICH – GCP Guidelines > Insurance

> Health Economics > Patent Law > Epidemiology

Drug Discovery / Delivery & Therapeutics > Toxicity Assays > Diabetes > Imaging Technologies (Safety & Testing) > Biopharmaceutical Lab Services

> Inhalation & Nasal Drug Delivery – MDI’s & DPI’s > Advances in Stem Cell Technology > Cardiovascular / Metabolic > Supporting Drug Safety

Clinical & Medical Research > Medical Imaging > Bio Equivalence Studies > SMO/ Site Management > Human Embryonic Stem Cells (hESCo)

> eCTD > Medical Devices > Pharmacovigilance & Drug Safety

Clinical Trials > Cardiovascular Safety / QTc Prolongation > Rescue Studies > Hepatic & Renal Impairment

> CTS/CTMS > CDISC/CDASH > Targeted Populations

Labs & Logistics > Global Central Laboratories > Safety Testing > RFID Tracking Systems > Emerging Markets Customs

> Cardiology > Time Sensitive Shipment > Optical Sensing

Manufacturing > Parenteral > Neutraceuticals > IV Drug Delivery > Filtration & Separation > Inhalation

> Semi Solids / Creams & Ointments > Topical > Robotics & CAM > Prefilled Injectable

Packaging > Labelling & Bar-coding > Translation & License Regulation > Booklet Labelling

> Patient Information Leafleting > Electronic Notification & Intelligent Packaging – to enhance patient compliance > Authentication & Brand Protection

Exhibitions & Conferences Attended by IPI with this issue:

> CPHI / ICSE / PMEC / BIOPH 2013 (Frankfurt) > BIO Partnering Future Europe > Scanbalt 2013

> BIO EUROPE – Autumn > Partnership in Clinical Trials Europe IPI is Peer Reviewed. Please refer to the Editorial Guidelines section on the www.ipimediaworld.com website for Peer Review Protocol and Authors Guidelines.


Volume 5 Issue 4 – November 2013 Submission deadline – 15th October 2013 Regulatory & Marketplace > FDA / EMEA / WHO – > Validation & Accreditation > Vaccines & Adjuvant – Prevention & Cure > FDA/EMA Submission Policies

> Helsinki Declaration – what it means in the current climate. > Cardiovascular Safety

Drug Discovery / Delivery & Therapeutics > Antibody Drugs for Oncology > Cell Processing Tools > Custom Antibodies > Prefilled Injection Systems > Cognitive Research

> Parenterals > Fragment Based Drug Design > Transdermal > CNS – Alzheimer’s

Clinical & Medical Research > Managing Adverse Reactions > Preclinical > IMP Manufacturing & Supply

> Phase I – IV > PharmacoEconomics > Medical Imaging

Clinical Trials > Imaging in Oncology > Temperature Controlled / Data logging in Clinical Trials Shipment > Central, Global, Analytical Labs

> Lab Validation > LIMS

Labs & Logistics > Lab Validation > Temperature Controlled/Data Logging in Clinical Trials Shipment

> Imaging in Oncology > LIMS

Manufacturing > Leak Detection & Vision System > FDA & EMEA Facility Compliance > Solid Dosage Form production > Filtration & Milling

> Quality Control & Quality Assurance > Environmental Protection & Facility Management > Raman Spectroscopy > Blending & Mixing Technologies

Packaging > Liquids & Sachets > Brand Protection > Prefilled Injection Systems > Clinical Trials Packaging

> Blistering & De-Blistering Machines > Sterile Fill Finish > RFID Coding & Marking

Exhibitions & Conferences Attended by IPI with this issue:

> IQPC Cool Chain 2013 > Genesis > BIO Partnering (Brussels)

> ICSE / CPHI / BIOPH / PMEC India

The topics and subjects listed above are special features and focuses. Please refer to the media information for a list of general topics that will be featured in IPI throughout 2013. Editorial topics listed above are subject to changes, according to the movement of the industry. We will be pleased to hear from you if you have relevant topics you would like to contribute within the journal. Please email all your suggestions to – info@pharmapubs.com Current News and Press Releases can also emailed to the above email address and will be hosted at – www.ipimediaworld.com, or featured in the IPI Weekly Newsletter at our discretion.


www. i pi me di a . c om www. j f or c s . c om www. j f or pc . c om

n ao s i n a g r co mi a n y dd n ha s e r Af . y r t s u d n eI c n e i c s e f i el h ot dt e t a c i d e d . . . n ao n i mb o gC n i n n AWi ’ d l Go r o gf n i Go ‘

P h a r maP u b l i c ao n s , T o we r B r i d g eB u s i n e s sC o mp l e x ,L o n d o nS E 1 64 DG, T e l : + 4 4 ( 0 ) 2 0 72 3 72 0 3 6 , E ma i l : I n f o @p h a r ma p u b s . c o m


International Pharmeceutical Industry